From COVID-19 vaccines to Moderna’s mRNA flu vaccine, using mRNA as medicine has shown promise. But before mRNA drugs can go beyond vaccines, researchers need to identify the right diseases to treat.
Articles on RNA therapeutics
Displaying all articles
Victor Ambros and Gary Ruvkun won the 2024 Nobel Prize in physiology or medicine for their discovery of microRNAs, molecules that turn genes on and off – and cause disease when they go awry.
Clinical trials look promising, and if these drugs are approved, would change how we manage high blood pressure. But there’s much we don’t know about these injectables.
The COVID-19 pandemic demonstrated the promise of using mRNA as medicine. But before mRNA drugs can go beyond vaccines, researchers need to identify the right diseases to treat.
From COVID-19 vaccines to cancer treatments and beyond, the flexibility of mRNA-based therapies gives them the potential to prevent and treat many types of diseases.
When just one of the thousands of microRNAs in people go awry, it can cause diseases ranging from heart disease to cancer.
Considered a pipe dream not too long ago, research on RNA therapeutics is progressing rapidly. Now a new manufacturing protocol will help researchers to advance the technology.
This is an era of exciting advances in medical science. But Africa is in danger of being at the back of the queue once again. What should we be doing to make sure this doesn’t happen?
Top contributors
-
Associate Professor of Biological Sciences, Purdue University
-
Assistant Professor of Biomedical Sciences, UMass Chan Medical School
-
Associate Professor of Biology, University of Richmond
-
Senior Professorial Fellow, George Institute for Global Health
-
Cardiologist and Research Fellow, Cardiovascular Program, George Institute for Global Health
-
SHARP Professor of Cardiovascular Medicine, UNSW
-
Senior Specialist in Molecular Biology, Malaghan Institute of Medical Research
-
Fellow, Nigerian Academy of Science